AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions. Its research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. AtriCure also pioneered the AtriClip LAA Exclusion System. The company collaborates with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, AtriCure is working to reduce the global atrial fibrillation epidemic.
Company Growth (employees)
Mason, US
Size (employees)
500 (est)
AtriCure was founded in 2000 and is headquartered in Mason, US

Key People/Management at AtriCure

Michael Carrel

Michael Carrel

President & CEO
Andrew Wade

Andrew Wade


AtriCure Office Locations

AtriCure has offices in Mason, West Chester, Minnetonka, San Ramon and in 28 other locations
Mason, US (HQ)
7555 Innovation Way
Minnetonka, US
250 130 Cheshire Ln
San Ramon, US
110 2420 Camino Ramon
West Chester, US
6217 Centre Park Drive
Amsterdam-Zuidoost, NL
260 De Entree
Show all (32)

AtriCure Financials and Metrics

AtriCure Financials

AtriCure's revenue was reported to be $155.1 m in FY, 2016

Revenue (Q3, 2017)

42.2 m

Gross profit (Q3, 2017)

30.9 m

Gross profit margin (Q3, 2017), %


Net income (Q3, 2017)

(7.2 m)

EBIT (Q3, 2017)

(6.8 m)

Market capitalization (16-Feb-2018)

552.5 m

Cash (30-Sep-2017)

19.4 m


551.7 m
AtriCure's current market capitalization is $552.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


81.9 m107.5 m129.8 m155.1 m

Revenue growth, %


Cost of goods sold

22.3 m31.7 m36.9 m44 m

Gross profit

59.6 m75.8 m92.9 m111.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


20.1 m24.8 m26.5 m26.7 m29.9 m32.6 m31.4 m35.9 m39.7 m38.3 m41.3 m45.2 m42.2 m

Cost of goods sold

5.5 m7.2 m7.7 m7.8 m8.2 m9.5 m8.9 m10 m10.9 m10.9 m11.3 m12.7 m11.2 m

Gross profit

14.7 m17.7 m18.8 m18.9 m21.7 m23.1 m22.5 m25.9 m28.8 m27.5 m30 m32.6 m30.9 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


14.9 m28.4 m23.8 m24.2 m


10.2 m14.3 m17.7 m17.7 m

Current Assets

52.5 m93.5 m74.8 m85.7 m


5.6 m11.6 m31.3 m30 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


25.8 m68.6 m42 m35.5 m23.6 m30 m28.7 m20.8 m19.9 m16.1 m19.2 m21 m19.4 m


7.1 m11.1 m12.7 m14.6 m15.1 m16.1 m16.6 m19 m19.3 m19 m18.8 m19.9 m22.6 m

Current Assets

48.6 m107.2 m92.8 m90.7 m93.4 m90.7 m84.1 m65.4 m86.5 m84.4 m79.1 m81.1 m82.1 m


4.1 m5.8 m6.5 m9.8 m13.9 m19.4 m27.5 m31.2 m30.9 m30.7 m29.9 m30 m29.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(11.5 m)(16.2 m)(27.2 m)(33.3 m)

Depreciation and Amortization

2 m4.8 m6.3 m9.3 m

Accounts Receivable

(1.2 m)(4.2 m)(900 k)(2 m)


(2.3 m)(4.3 m)(3 m)(79 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.7 m)(7.7 m)(2.7 m)(466 k)(5.3 m)(4.9 m)(6.1 m)(9.7 m)(8.2 m)(6.8 m)(10.2 m)


12.7 m14.6 m15.1 m16.1 m16.6 m19 m19.3 m19 m18.8 m

Accounts Payable

7.5 m7.8 m9.7 m9.3 m11.2 m12.8 m11.9 m11 m11.3 m
USDY, 2017


-80.6 x


84.3 k

Financial Leverage

1.7 x
Show all financial metrics

AtriCure Market Value History

AtriCure's Web-traffic and Trends

AtriCure Online and Social Media Presence

AtriCure Company Life and Culture

You may also be interested in